Currently there are no upcoming events.
Dr. Philip Greenberg of the University of Washington discusses how cutting-edge strategies using T cells from patients’ blood are currently being used in the clinic as well as how they might be improved moving forward.
Ariella Chivil, a patient advocate, and Dr. Alexander M. Lesokhin, her oncologist, discuss the nuances of communicating and informing both doctor and patient while on immunotherapy.
Dr. John Bell of the University of Ottawa and the Ontario Institute for Cancer Research discussses strategies that re-program viruses so that they selectively infect and kill cancer cells while leaving healthy cells and tissues unharmed.
Cancer patients T.J. Sharpe and Donna Fernandez share their experiences with immunotherapy and advice for patients currently seeking or receiving immunotherapy treatment.
Patrick Meins of EmergingMed will answer common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
Dr. John B. Liao of the University of Washington discusses the immunotherapy landscape for patients with ovarian cancer.
Dr. Dustin A. Deming of the University of Wisconsin Carbone Cancer Center discusses the most effective immunotherapies currently available to patients with stomach, gastrointestinal (GI), and colorectal (CRC) cancers.
Dr. Robert D. Schreiber of of Washington University School of Medicine in St. Louis discusses how advances in our understanding of genomics have enabled doctors to identify the mutations driving individual tumors.
Cancer Research Institute | National Headquarters 29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We introduce you to Rafael Amado, M.D., chief medical officer at Adaptimmune, a leader in T cell receptor (TCR) cancer immunotherapy.
On June 30, 2018, over 200 patients, caregivers, and advocates gathered to connect with experts and learn about the science of cancer immunotherapy in San Francisco.